According to the Digital Therapeutics Alliance , Digital Therapeutics (DTx) deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes.
DTx products incorporate advanced technology best practices relating to design, clinical validation, usability, and data security. They are validated by regulatory bodies as required to support product claims regarding risk, efficacy, and intended use. Digital therapeutics empower patients, healthcare providers, and payers with intelligent and accessible tools for addressing a wide range of conditions through high quality, safe, and effective data-driven interventions.
Digital therapeutics form an independent category of evidence-based products within the broader digital health landscape. Digital therapeutics are distinguished from other digital health categories through their primary function of delivering software-generated therapeutic interventions directly to patients to prevent, manage, or treat a medical disorder or disease.
Digital Therapeutics provide information and can be used alongside face-to-face physician consultancy. Many digital therapeutics initiatives can be used to support treatment as well as function as lifestyle tools to help manage health and well-being. As such, Digital Therapeutics technologies are used both as stand-alone and in combination with conventional therapies.
Access Market Intelligence’s inaugural Digital Therapeutics Insight line focuses on DTx in the commercial insurance market. Our service includes an industry database, landscape and trend reports, custom research, and strategy consulting with an emphasis on market access and reimbursement. Previously published reports in this series include:
- Digital Therapeutics in the Diabetes Market
- Digital Therapeutics in the Behavioral Health Market
- Direct to Consumer Pharmacies Overview
|Application||Type||DTx Company||Partners||End User||Reimbursement|
AMI’s new report: Digital Therapeutics in the Central Nervous System Market, provides a brief overview of the CNS market and profiles the digital therapeutic companies offering products and services. DTx company profiles include: address, website, executive contacts, background, products, partners, end users, and recent activities.
The Table of Contents include:
Digital Therapeutics Introduction – pgs. 4-5
Central Nervous System Overview – pgs. 6-8
Digital Therapeutic Company Profiles – pgs. 9-51
- Altoida – pg. 11
- Amalgam Rx – pgs. 12-13
- BeCareLink – pgs. 14-15
- Better Therapeutics – pgs. 16-17
- BlackThorn Therapeutics – pgs. 18-20
- Closed Loop Medicine – pgs. 21-22
- Cognivive – pg. 23
- Dthera Sciences – pgs. 24-25
- GAIA AG – pgs. 26-28
- Hinge Health – pgs. 29-30
- JOGO Health – pgs. 31-32
- MedRhythms, Inc. – pgs. 33-34
- Mentia.me – pg. 35
- Mymee – pg. 36
- Neurotrack Technologies – pgs. 37-38
- Pear Therapeutics – pgs. 39-41
- SetPoint Medical – pgs. 42-44
- Sonde Health – 45-46
- SWORD Health – pgs. 47-48
- VIz.ai – pgs. 49-51
- References/Sources – pg. 52